Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease

Next Previous
Trial Profile

Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms ASSERT
  • Sponsors Resverlogix Corporation

Most Recent Events

  • 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
  • 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
  • 16 Nov 2016 Results of post hoc analysis of phase IIb ASSERT and ASSURE trials (n=51), presented at the 89th Annual Scientific Sessions of the American Heart Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top